The journey through the slipstream, though brief in absolute terms, required constant vigilance. The quantum conduit, while stable, was not immune to cosmic events. Helios logged a total of 84 micro‑fluctuations per hour—tiny ripples that, if left unchecked, could amplify into a full‑scale slipstream collapse.
The crew settled into a rhythm:
Triple‑negative breast cancer (TNBC) accounts for ~15‑20 % of all breast cancers and is characterized by an aggressive clinical course, early metastasis, and a paucity of targeted therapies (1). Genomic analyses have highlighted the phosphatidylinositol‑3‑kinase (PI3K)/AKT/mTOR axis as a central driver of proliferation, survival, and chemoresistance in TNBC (2,3). While several pan‑class I PI3K inhibitors have entered clinical testing, dose‑limiting toxicities—particularly hyperglycemia, rash, and immune suppression—have limited their therapeutic window (4). Consequently, there is a critical need for next‑generation PI3K inhibitors with improved selectivity, oral bioavailability, and tumor‑specific activity. MEYD-773
Here we report the discovery and preclinical characterization of MEYD‑773, a novel heterocyclic small‑molecule inhibitor derived from a 1,3‑thiazolo[5,4‑d]pyrimidine scaffold. MEYD‑773 was optimized through structure‑activity relationship (SAR) studies to achieve high potency against the p110α catalytic subunit of PI3K, while sparing other class I isoforms (p110β, p110δ, p110γ) and unrelated kinases. We hypothesized that this selectivity would translate into a favorable safety profile and allow sustained inhibition of oncogenic PI3K signaling in TNBC.
Background: Triple‑negative breast cancer (TNBC) lacks expression of estrogen, progesterone, and HER2 receptors, limiting therapeutic options. Hyperactivation of the PI3K/AKT signaling axis is a frequent driver of TNBC progression and resistance to chemotherapy. MEYD‑773: The Long‑Haul Between Stars 3
Objective: To characterize the pharmacological profile, mechanism of action, and in‑vivo efficacy of MEYD‑773, a newly synthesized heterocyclic scaffold designed to selectively inhibit class I PI3K isoforms.
Methods: A combinatorial library of 1,3‑thiazolo[5,4‑d]pyrimidine derivatives was screened for PI3K inhibition. MEYD‑773 (chemical name: 6‑[(4‑fluorophenyl)amino]‑2‑(pyridin‑3‑yl)‑1,3‑thiazolo[5,4‑d]pyrimidine) was identified as the lead compound (IC₅₀ = 12 nM for p110α). Kinase selectivity was assessed against a 340‑kinase panel. Cellular activity was evaluated in a panel of breast cancer cell lines (MDA‑MB‑231, HCC‑1806, BT‑549, MCF‑7, and T‑47D). Apoptosis, cell‑cycle distribution, and downstream signaling were examined by flow cytometry, western blot, and phospho‑proteomics. Pharmacokinetics (PK) and tolerability were studied in CD‑1 mice. Antitumor efficacy was tested in orthotopic TNBC xenografts and patient‑derived xenograft (PDX) models. 08:00 – 09:30 – Navigation & Slipstream Adjustment
Results: MEYD‑773 displayed >250‑fold selectivity for class I PI3K over other kinases, with negligible activity against mTOR, DNA‑PK, and CDK families. In vitro, MEYD‑773 reduced p‑AKT (Ser473) and p‑S6 (Ser235/236) levels with EC₅₀ ≈ 30 nM, induced G₁ arrest, and triggered caspase‑3/7‑mediated apoptosis selectively in PI3K‑mutant TNBC cells (IC₅₀ = 0.08‑0.15 µM). PK studies revealed oral bioavailability of 68 %, a half‑life of 7.2 h, and plasma exposure exceeding the in‑vitro EC₅₀ for >12 h at 20 mg kg⁻¹. In orthotopic MDA‑MB‑231 models, daily oral dosing (20 mg kg⁻¹) produced a tumor growth inhibition (TGI) of 82 % (p < 0.001) without weight loss or histopathologic toxicity. In three independent TNBC PDX models (BRCA1‑mutated, PTEN‑null, and wild‑type PI3K), MEYD‑773 achieved TGIs of 71‑89 % and prolonged median survival by 3‑4‑fold compared with vehicle. Combination with standard‑of‑care paclitaxel showed synergistic tumor regression (Combination Index = 0.46).
Conclusions: MEYD‑773 is a highly selective, orally bioavailable PI3K inhibitor with robust preclinical activity against TNBC, including chemoresistant subtypes. These data support advancement of MEYD‑773 into IND‑enabling studies and a first‑in‑human phase I trial in patients with advanced PI3K‑driven TNBC.
Keywords: MEYD‑773, PI3K inhibitor, triple‑negative breast cancer, targeted therapy, preclinical development
A library of 1,3‑thiazolo[5,4‑d]pyrimidine derivatives was synthesized via a three‑step condensation of 2‑amino‑4‑fluorobenzaldehyde, 3‑pyridinecarboxaldehyde, and thiourea under microwave‑assisted conditions (5). The lead compound MEYD‑773 (C₁₈H₁₃FN₅S) was purified by preparative HPLC (purity > 99 %). Structural confirmation was achieved by ^1H/^13C NMR, HR‑MS, and X‑ray crystallography (PDB ID 8XYZ).
